Molecular pathophysiology and targeted therapeutics for muscular dystrophy

Publisher： Elsevier

ISSN： 0165-6147

Source： Trends in Pharmacological Sciences, Vol.22, Iss.9, 2001-09, pp. : 465-470

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

By Judge Daniel P. Kass David A. Thompson W. Reid Wagner Kathryn R.

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 5, 2011-10 ,pp. : 287-294

Adis International

Access to resources Recommend Favorite

Personalised molecular medicine possible in muscular dystrophy?

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Molecular Features, Markers, Drug Targets, and Prospective Targeted Therapeutics in Cardiac Myxoma

Current Cancer Drug Targets, Vol. 9, Iss. 6, 2009-09 ,pp. : 705-716

Bentham Science Publishers

Access to resources Recommend Favorite

Glutamate and Schizophrenia: Pathophysiology and Therapeutics

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 2, Iss. 1, 2002-03 ,pp. : 29-44

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for Duchenne muscular dystrophy

By Malik Vinod Rodino-Klapac Louise R. Mendell Jerry R

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 2, 2012-06 ,pp. : 261-277

Informa Healthcare

Access to resources Recommend Favorite